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INTRODUCTION
Cannabis sativa is a plant containing
over 70 active compounds called cannabi-
noids (Schoedel and Harrison, 2012). The
psychoactive effects of cannabinoids are
abused worldwide by about 20% of young
people, who report regular or heavy use
of the cannabis plant (Moore et al., 2007).
Delta-9-tetrahydrocannabinol (THC), the
most prevalent cannabinoid in the plant,
has been found to be responsible for pro-
ducing most of the desirable effects of
marijuana (Gaoni and Mechoulam, 1964).
In line with that, the use of modern
hydroponic cannabis farms has resulted in
growing strains containing higher levels of
THC, while keeping other cannabinoids
at negligible levels (Hardwick and King,
2008). Accordingly, it may be assumed
that the presence of THC-dominated
cannabis plants on the market leads to
the risk of more severe consequences
of abuse, since THC has been associ-
ated with induction of psychotic symp-
toms both in an acute intoxicated state
(D’Souza et al., 2004), as well as in
the long-term (Kuepper et al., 2010).
Consequently, in the current paper we
propose that cannabidiol (CBD), another
abundant compound of cannabis, might
have an impact on cognition and emo-
tional processing, which is opposite to
the effect of THC. Moreover, we suggest
that the effects of CBD would be worth
investigating in regard to the modula-
tory role of the anterior cingulate cortex
(ACC)—a brain region where both affec-
tive and cognitive information converge
(Bush et al., 2000; Botvinick et al., 2001;
Paus, 2001).
The pharmacology of CBD is well
studied [for a review see Mechoulam
et al. (2002)]. Its effects are distinct
and frequently opposite to those of THC
(Fusar-Poli et al., 2009). Whereas THC
is a cannabinoid receptor type 1 and
2 (CB1r and CB2r) agonist, CBD has
low affinity and a partially antagonistic
effect at these receptors (Pertwee, 2008).
Furthermore, CBD has been shown to
be a serotonin receptor (5-HTr) agonist
(Campos and Guimarães, 2008; Zanelati
et al., 2010; Gomes et al., 2011). In
recent years CBD has received renewed
attention from researchers, mainly due to
its anxiolytic (e.g., Zuardi et al., 1982,
1993; Crippa et al., 2004, 2011; Fusar-Poli
et al., 2009; Bergamaschi et al., 2011) and
antipsychotic effects (e.g., Zuardi et al.,
2009; Bhattacharyya et al., 2010; Schubart
et al., 2011). The therapeutic value of
CBD in clinical contexts is currently being
explored (Zuardi et al., 2006, 2009; Hallak
et al., 2009). Moreover, in a recent review
Schier et al. (2012) suggested that CBD
neither produces psychoactive effects, nor
has an impact on cognition. In the light
of up-to-date research, this claim may be
considered unwarranted, since CBD has
been shown to differ with THC in terms
of activation of brain regions during tasks
involving response inhibition (Borgwardt
et al., 2008), emotional processing (Fusar-
Poli et al., 2009) and verbal memory
(Bhattacharyya et al., 2010). Additionally,
as far as only the anxiolytic effect of CBD
is considered, it may be assumed that it
influences cognition through, for instance,
reducing attention bias toward threat-
ening stimuli (Bar-Haim et al., 2007).
In spite of that, the effect of CBD on
cognitive performance has been largely
unexplored.
EFFECT OF CBD ON THE ACC
CBD is associated with increased resting
cerebral regional blood flow (rCBF) in the
left parahippocampal gyrus and decreased
rCBF in the amygdala-hippocampus com-
plex, including the posterior cingulate
cortex (Crippa et al., 2004). A functional
neuroimaging (fMRI) study found evi-
dence for attenuation of the blood-oxygen
level dependent (BOLD) signal in the
amygdala and the posterior and ACC in
response to the presentation of fearful
faces, combined with a reduction in sub-
jective anxiety (Fusar-Poli et al., 2009).
CBD also disrupts the functional con-
nectivity between the ACC and amyg-
dala (Fusar-Poli et al., 2010). Taken
together, these results point to both an
anxiolytic effect of CBD and a critical
modulatory role of the ACC. However,
Bhattacharyya et al. (2010) found no effect
of CBD on ACC activity in a task iden-
tical to the one used by Fusar-Poli et al.
(2009)—a discrepancy we will be getting
back to. To summarize, apart from the
emotion-regulating properties of CBD, the
CBD–ACC relationship has not been sys-
tematically investigated.
Accordingly, it would be worthwhile
to examine how the impact of CBD on
ACC activity may extend to the domain
of cognitive performance. Since modu-
lation of ACC activity is assumed to
be the mechanism through which CBD
affects brain connectivity during emo-
tional processing (Fusar-Poli et al., 2010),
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it might be suspected that the ACC is
also the main target for CBD in terms of
potential cognition-altering effects of the
compound. Previous research has iden-
tified the ACC as an important relay
station for cognitive control processes
and as a region that integrates cogni-
tive and emotional information (Bush
et al., 2000; Botvinick et al., 2001; Paus,
2001). It is then possible that CBD has an
effect on conflict monitoring - a process
which monitors for the presence of con-
flicts in information processing. Conflict
monitoring exerts top-down control over
information processing by focusing atten-
tion on task-relevant processing streams,
while blocking off task-irrelevant channels
(Botvinick et al., 2001). In line with that,
positron emission tomography (PET) and
fMRI studies reliably show ACC activation
in tasks in which subjects need to override
automatic, but otherwise task-irrelevant
responses, such as the Stroop Color Word
Test (SCWT; Pardo et al., 1990; Carter
et al., 1995; Bush et al., 1998) and go/no-
go tasks (Kawashima et al., 1996; Casey
et al., 1997). Since CBD has been shown
to decrease activity in the ACC (Fusar-Poli
et al., 2009, 2010), it may be suspected
that individuals treated with CBD are less
likely to suppress their dominant response
(Casey et al., 1997), or become aware of
committing a mistake (Holroyd and Coles,
2002).
EFFECT OF CBD ON COGNITION
Taken together, research regarding the
impact of CBD on ACC activity appears
to be contradictory (see Table 1): CBD
has been reported to attenuate ACC
activity (Fusar-Poli et al., 2009, 2010),
have no effect (Borgwardt et al., 2008;
Bhattacharyya et al., 2009, 2010), or
even enhance ACC activity (Bhattacharyya
et al., 2010). One possible explanation for
these contradictory observations may be
found in the type of tasks used in the
studies mentioned and, thus, the func-
tions which they relate to. In the case of
cognition, keeping in mind the involve-
ment of the ACC in conflict monitor-
ing (Bush et al., 2000; Botvinick et al.,
2001; Paus, 2001), it would be worth-
while to have a closer look at the find-
ings of Bhattacharyya et al. (2010). The
observed increased activity of the ACC
during a verbal recall task is in line with
research showing lack of impairment of
verbal memory in cannabis users intox-
icated with high-CBD content cannabis
(4.61% on average), as opposed to those
that used low-CBD content plant mate-
rial (0.08% on average; Morgan et al.,
2010). Furthermore, it has been suggested
that the memory-protective effect of CBD
extends into the long-term (Morgan et al.,
2012). Combining the results of the above-
mentioned studies, one could claim that
the CBD-induced improvement is not
restricted to the domain of memory itself,
but reflects a more general enhance-
ment of the conflict monitoring system.
Additionally, such a claim becomes some-
what more plausible when one takes into
account a recent investigation which found
a trend for decreased response latency to
oddball stimuli following CBD admin-
istration together with, surprisingly, an
attenuating effect on the medial pre-
frontal cortex (Bhattacharyya et al., 2012).
Although this opposite effect of CBD on
activation and the finding of no effect of
CBD on ACC activity in another study
applying the verbal recall task make the
case less clear (Bhattacharyya et al., 2009),
it is possible that the beneficial effect of
CBD is more visible in case of modulat-
ing the deteriorating effects of THC than
when administered alone. Since THC is a
CB1r and CB2r agonist, the opposite, par-
tially antagonistic, effect of CBD on CB1rs
and CB2rs suggests that it may protect
against the deterioration of cognitive per-
formance caused by THC (Pertwee, 2008).
THC has been shown to decrease the
error-related negativity—an event-related
Table 1 | Functional MRI studies of the cognitive and emotional effects of cannabidiol.
Sample size CBD dose*** Route Task ACC activation Amygdala Anxiolytic
activation effect
COGNITION
Borgwardt et al. (2008) 15 600mg Oral Response inhibition
(go/no-go)
n.s. n.s. p = 0.06
Bhattacharyya et al. (2009) 15 600mg Oral Verbal paired associate
learning
n.s. n.s. n.s.
Bhattacharyya et al. (2010)* 15 600mg Oral Verbal paired associate
learning
p < 0.01 n.s. p = 0.06
EMOTION
Fusar-Poli et al. (2009) 15 600mg Oral Facial expressions of
emotion: stimuli and tests
p < 0.05 p < 0.05 p = 0.06
Bhattacharyya et al. (2010)* 15 600mg Oral Facial expressions of
emotion: stimuli and tests
n.s. p < 0.05 p = 0.06
Fusar-Poli et al. (2010)** 15 600mg Oral Facial expressions of
emotion: stimuli and tests
p < 0.05 p < 0.05 n/a
*Contrasted with effects of delta-9-tetrahydrocannabinol (10 mg, 99.6% pure).
**Dynamic causal modeling—significant activation indicating a difference in the forward intrinsic connection between ACC and amygdala.
***99.9% pure in all studies.
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potential indicative of conflict monitoring
and assumed to be generated by the ACC
(Spronk et al., 2011). Given the oppos-
ing neuropharmacological actions of the
two compounds, one may then expect that
CBD will inhibit the impact of THC on the
ACC. On the other hand, in the absence of
THC, partial antagonism of CB1rs might
not be sufficient to produce overt changes
in the conflict monitoring system, either
at the behavioral or the neurophysiological
level. Accordingly, it would be worthwhile
to explore whether the THC-protective
effects of CBD can be related directly to
ACC functioning.
EFFECT OF CBD ON AFFECTIVE
PROCESSING
It is also interesting to consider the ACC-
mediated impact of CBD on emotional
processing. Animal research indicates that
the anxiolytic effect of CBD depends on
action of the compound on specific brain
areas and that the effect could also, in some
cases, be anxiogenic (Marco et al., 2011).
In case of human studies, it can be hypoth-
esized that CBD decreases ACC activity,
which would be in line with the anxi-
olytic effect of the compound (Fusar-Poli
et al., 2009). The concurrent reduction
in amygdala BOLD response associated
with presentation of fearful faces gives fur-
ther support to this assumption, given the
involvement of this region in fear process-
ing and its anatomical connection with
the ACC (Fusar-Poli et al., 2009, 2010;
Bhattacharyya et al., 2010). However,
while both Fusar-Poli et al. (2009) and
Bhattacharyya et al. (2010) found a trend
in reduction of subjective anxiety follow-
ing CBD administration, only the former
was able to observe a related decrease
in ACC activation during emotional pro-
cessing. In case of the latter, the authors
explain the lack of a possible effect by a
selective analysis of brain areas where THC
and CBD had opposite effects, instead
of assessing the effects of the two com-
pounds separately (Bhattacharyya et al.,
2010). However, the fact that application
of the same design, task and subject sample
led to different results throws some doubt
on the importance of the ACC in mediat-
ing the effects of CBD on brain connec-
tivity (Fusar-Poli et al., 2010). Moreover,
if one were to follow the logic of Fusar-
Poli et al. (2010) about top-down control
of the ACC over the amygdala, attenua-
tion of the amygdala BOLD response in the
Bhattacharyya et al. (2010) study should
not have been observed without a simulta-
neous effect in the ACC. In principle, the
anxiolytic effects of CBD are assumed to
be mediated by the ACC, which, in turn,
affects activity of the amygdala (Fusar-Poli
et al., 2010). Therefore, from this per-
spective, it is surprising that the reduc-
tion in subjective anxiety observed by
Bhattacharyya et al. (2010) was indeed
associated with a concurrent decrease in
amygdala activation, but not the ACC.
If the ACC actually plays a critical role
in moderating the anxiolytic effects of
CBD (Fusar-Poli et al., 2010), then it
seems plausible to expect an effect in
this brain region, even when keeping in
mind the selective analysis of opposing
effects of THC and CBD on activation
(Bhattacharyya et al., 2010). On the other
hand, the absence of an effect of CBD may
alternatively be explained by the lack of
a significant linear relationship between
the effects of the two drugs and placebo.
Consequently, the fact that Bhattacharyya
et al. (2010) did not find CBD to be asso-
ciated with decreased ACC activity, is not
necessarily equivalent to the lack of an
effect of CBD relative to a placebo con-
dition. In any case, apart from evidence
pointing to a link between CBD and the
ACC in emotional processing, it is likely
that this connection is not as straight-
forward as suggested by Fusar-Poli et al.
(2010).
SUMMARY
In sum, existing research seems to under-
mine Schier’s et al. (2012) suggestion
regarding the lack of a relationship
between CBD and cognition. Rather,
it seems that both cognitive and affec-
tive consequences of CBD administration
may be mediated by the ACC. However,
the lack of clear-cut results renders the
extent and nature of this modulation
unclear. The diversity of findings may
be explained by various factors, includ-
ing differential activation of the cognitive
and affective subdivisions of the ACC
(Bush et al., 2000), the slow onset of
action and inconsistent bioavailabil-
ity of orally administered cannabinoids
(Hazekamp et al., 2006), the dosage of
CBD (Marco et al., 2011), or whether
CBD was administered alone, or in com-
bination with THC (Pertwee, 2008).
Furthermore, since modulation of the
cognitive effects of cannabinoids has
been linked to polymorphism of the
cannabinoid receptor (CNR1) gene (Beng-
Choon et al., 2011; Stadelman et al.,
2011), it is possible that some genetic
predispositions of the studied samples
could have influenced the results. From
this perspective, also the catechol-O-
methyltransferase (COMT) gene seems
to be a plausible moderating factor due
to its role in cognitive control (Colzato
et al., 2010) and the pharmacological
interactions between the endocannabi-
noid and dopamine systems (Fattore et al.,
2010). In any case, inclusion of new vari-
ables could further clarify the CBD–ACC
relationship and its role in the aspects
of conflict monitoring and emotional
processing.
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